Alpha‐lipoic acid as a preventive measure in radiation‐induced oral mucositis in head and neck cancer patients: A randomized controlled study
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70497 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Beshoy Anwar Rizkalla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Thioctic Acid, Stomatitis, Head and Neck Neoplasms, Radiation Injuries. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
Alpha‐lipoic acid (ALA), a potent antioxidant, anti‐inflammatory and cytoprotective drug, has revealed potential efficacy in pre‐clinical studies in reducing radiation induced oral mucositis (RIOM). This study aims to evaluate the protective effects of ALA on RIOM.
Methods
In this randomized controlled study, 70 head and neck cancer (HNC) patients receiving definitive radiotherapy were assigned to receive either oral ALA (600 mg twice daily) or placebo tablets throughout the radiotherapy period. The primary outcome was the assessment of the incidence and severity of RIOM using the Radiotherapy Oncology Group (RTOG) grading system. Secondary outcomes were the onset and duration of severe RIOM (Grades 3 and 4), quality of life (QOL), and serum total antioxidant capacity (TAC) and C‐reactive protein (CRP).
Results
The incidence of severe RIOM was 16.7% with the use of ALA, while in the control group it was 41.3% ( p value = 0.036). Moreover, ALA significantly delayed the occurrence of severe RIOM ( p value = 0.033) and resulted in significantly shorter healing time ( p value = 0.042). At the end of the study, ALA resulted in a mean percent change in QOL score from baseline of 43.33, which was non‐significantly different from the control group with a mean of 44.84. ALA significantly improved TAC levels but had no effect on CRP. The use of ALA was safe and tolerable.
Conclusion
ALA showed a significant reduction in the severity and delayed the onset of RIOM with a high safety profile through its potent antioxidant effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
- Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
ORCID-Profile: Mohamed Reda Kelany, Nagwa Ali Sabri, May Ahmed Shawki
Zitieren
APA
Rizkalla, B. A., Kelany, M. R., Sabri, N. A., & Shawki, M. A. (2026). Alpha‐lipoic acid as a preventive measure in radiation‐induced oral mucositis in head and neck cancer patients: A randomized controlled study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70497
Vancouver
Rizkalla BA, Kelany MR, Sabri NA, Shawki MA. Alpha‐lipoic acid as a preventive measure in radiation‐induced oral mucositis in head and neck cancer patients: A randomized controlled study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70497
BibTeX
@article{Rizkalla2026,
author = {Rizkalla, Beshoy Anwar and Kelany, Mohamed Reda and Sabri, Nagwa Ali and Shawki, May Ahmed},
title = {Alpha‐lipoic acid as a preventive measure in radiation‐induced oral mucositis in head and neck cancer patients: A randomized controlled study},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70497}
}
EUVIMED